Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms without new clinical data or systematic trial synthesis
PubMed 31439934 · doi:10.1038/s41574-019-0242-2
What was done
This is a narrative review synthesizing literature on the cellular, hepatic, gastrointestinal, and immunological mechanisms responsible for the glucose-lowering effects of metformin in type 2 diabetes mellitus.
What was found
The abstract reports no numerical data. It outlines multiple proposed pathways of metformin action: suppression of hepatic glucose production; inhibition of mitochondrial complex 1; non-AMPK mediated inhibition of gluconeogenesis via adenylate cyclase, fructose-1,6-bisphosphatase 1, and mitochondrial glycerol-3-phosphate dehydrogenase; reduction of meta-inflammation in adipose tissue, liver, and gut; and gastrointestinal effects involving glucagon-like peptide 1, bile acid metabolism, and gut microbiota composition.
Why it matters
It highlights that metformin's antidiabetic efficacy stems from complex, multi-organ pathways rather than a single AMPK-dependent hepatic mechanism.
Limits
This is a narrative review without systematic search criteria or primary experimental data. The abstract provides no quantitative effect sizes, patient counts, or clinical outcomes.
Cited by
- supports The diabetes drug metformin acts to stimulate AMP kinase.